Transaction DateRecipientSharesTypePriceValue
7th January 2021Advisors Llc Orbimed2,000,000Open or private sale$3.50$7,000,000.00
28th December 2020Peter A. Thompson600,000Open or private sale$14.25$8,550,000.00
28th December 2020Advisors Llc Orbimed600,000Open or private sale$14.25$8,550,000.00
8th December 2020Advisors Llc Orbimed952,377Open or private purchase$21.00$19,999,917.00
8th December 2020Advisors Llc Orbimed1,055,287Conversion of derivative$0.00
8th December 2020Advisors Llc Orbimed21,400Open or private sale$1.96$41,944.00
8th December 2020Peter A. Thompson238,100Open or private purchase$21.00$5,000,100.00
8th December 2020Advisors Llc Orbimed21,400Exercise of in-the-money or at-the-money derivatives securities (usually options)$0.96$20,544.00
8th December 2020Advisors Llc Orbimed3,462,737Conversion of derivative$0.00
8th December 2020Advisors Llc Orbimed2,493,741Conversion of derivative$0.00
Corvus Pharmaceuticals
Corvus Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Corvus Pharmaceuticals, Inc. engages in the development and commercialization of oncology therapies. The company focuses on disabling cancer's ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444.

Ticker: CRVS
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1626971
Employees: 53
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $21 M (301%)
Other Assets, Current: $413 Th (-15%)
Assets, Current: $61 M (-23%)
Property, Plant and Equipment, Net: $1 M (0%)
Other Assets, Noncurrent: $501 Th (-2%)
Assets: $64 M (-23%)
Accounts Payable, Current: $3 M (13%)
Liabilities, Current: $12 M (12%)
Liabilities: $13 M (6%)
Common Stock, Value, Issued: $3 Th (0%)
Common Stock, Shares, Issued: $28 M (0%)
Additional Paid in Capital, Common Stock: $291 M (1%)
Retained Earnings (Accumulated Deficit): $241 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $53 Th (82%)
Stockholders' Equity (Parent): $51 M (0%)
Liabilities and Equity: $64 M (-23%)
Research and Development: $8 M (-56%)
General and Administrative Expenses: $3 M (-51%)
Operating Income/Loss: $11 M (-55%)